Anavex Life Sciences’ (AVXL) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note issued to investors on Monday,Benzinga reports. D. Boral Capital currently has a $46.00 price objective on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Anavex Life Sciences in a research report on Monday, November 4th.

Anavex Life Sciences Trading Down 0.1 %

Anavex Life Sciences stock opened at $9.03 on Monday. The stock’s 50 day moving average is $6.54 and its 200-day moving average is $5.62. The company has a market capitalization of $765.74 million, a price-to-earnings ratio of -18.10 and a beta of 0.60. Anavex Life Sciences has a 12 month low of $3.25 and a 12 month high of $10.45.

Institutional Investors Weigh In On Anavex Life Sciences

Several large investors have recently bought and sold shares of AVXL. Vanguard Group Inc. increased its position in Anavex Life Sciences by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock valued at $22,471,000 after buying an additional 54,034 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Anavex Life Sciences by 2.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock valued at $10,699,000 after buying an additional 51,946 shares in the last quarter. Nwam LLC acquired a new position in Anavex Life Sciences during the third quarter worth $5,172,000. Charles Schwab Investment Management Inc. raised its position in shares of Anavex Life Sciences by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 14,892 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after acquiring an additional 386,537 shares in the last quarter. Institutional investors own 31.55% of the company’s stock.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.